294 related articles for article (PubMed ID: 33733472)
1. Food constituent- and herb-drug interactions in oncology: Influence of quantitative modelling on Drug labelling.
Pilla Reddy V; Jo H; Neuhoff S
Br J Clin Pharmacol; 2021 Oct; 87(10):3988-4000. PubMed ID: 33733472
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
Adiwidjaja J; Boddy AV; McLachlan AJ
Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
[TBL] [Abstract][Full Text] [Related]
3. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond!
Nowack R
Nephrology (Carlton); 2008 Jun; 13(4):337-47. PubMed ID: 18363644
[TBL] [Abstract][Full Text] [Related]
4. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
[TBL] [Abstract][Full Text] [Related]
5. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).
Markowitz JS; DeVane CL
Psychopharmacol Bull; 2001; 35(1):53-64. PubMed ID: 12397870
[TBL] [Abstract][Full Text] [Related]
6. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
[TBL] [Abstract][Full Text] [Related]
7. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.
Borrelli F; Izzo AA
AAPS J; 2009 Dec; 11(4):710-27. PubMed ID: 19859815
[TBL] [Abstract][Full Text] [Related]
8. St Johns wort increases expression of P-glycoprotein: implications for drug interactions.
Hennessy M; Kelleher D; Spiers JP; Barry M; Kavanagh P; Back D; Mulcahy F; Feely J
Br J Clin Pharmacol; 2002 Jan; 53(1):75-82. PubMed ID: 11849198
[TBL] [Abstract][Full Text] [Related]
9. Is the clinical relevance of drug-food and drug-herb interactions limited to grapefruit juice and Saint-John's Wort?
Mouly S; Lloret-Linares C; Sellier PO; Sene D; Bergmann JF
Pharmacol Res; 2017 Apr; 118():82-92. PubMed ID: 27693910
[TBL] [Abstract][Full Text] [Related]
10. Hyperforin in St. John's wort drug interactions.
Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
[TBL] [Abstract][Full Text] [Related]
11. Herbal modulation of P-glycoprotein.
Zhou S; Lim LY; Chowbay B
Drug Metab Rev; 2004 Feb; 36(1):57-104. PubMed ID: 15072439
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with St John's wort : mechanisms and clinical implications.
Mannel M
Drug Saf; 2004; 27(11):773-97. PubMed ID: 15350151
[TBL] [Abstract][Full Text] [Related]
13. An update on clinical drug interactions with the herbal antidepressant St. John's wort.
Zhou SF; Lai X
Curr Drug Metab; 2008 Jun; 9(5):394-409. PubMed ID: 18537576
[TBL] [Abstract][Full Text] [Related]
14. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic interactions of drugs with St John's wort.
Zhou S; Chan E; Pan SQ; Huang M; Lee EJ
J Psychopharmacol; 2004 Jun; 18(2):262-76. PubMed ID: 15260917
[TBL] [Abstract][Full Text] [Related]
16. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
Wang EJ; Barecki-Roach M; Johnson WW
J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
[TBL] [Abstract][Full Text] [Related]
17. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?
Gutmann H; Poller B; Büter KB; Pfrunder A; Schaffner W; Drewe J
Planta Med; 2006 Jun; 72(8):685-90. PubMed ID: 16755466
[TBL] [Abstract][Full Text] [Related]
18. Clinical drugs that interact with St. John's wort and implication in drug development.
Di YM; Li CG; Xue CC; Zhou SF
Curr Pharm Des; 2008; 14(17):1723-42. PubMed ID: 18673195
[TBL] [Abstract][Full Text] [Related]
19. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
20. Application of Cryopreserved Human Intestinal Mucosa and Cryopreserved Human Enterocytes in the Evaluation of Herb-Drug Interactions: Evaluation of CYP3A Inhibitory Potential of Grapefruit Juice and Commercial Formulations of Twenty-Nine Herbal Supplements.
Loretz C; Ho MD; Alam N; Mitchell W; Li AP
Drug Metab Dispos; 2020 Oct; 48(10):1084-1091. PubMed ID: 32719085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
